[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 937
Citations 0
Invited Commentary
April 2018

The SCORE2 Comparison of Treat-and-Extend vs Monthly Anti–Vascular Endothelial Growth Factor Dosing: Short-term Similarities and Longer-term Questions

Author Affiliations
  • 1Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts
  • 2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • 3CME Editor, JAMA Ophthalmology
JAMA Ophthalmol. 2018;136(4):346-347. doi:10.1001/jamaophthalmol.2017.6855

Therapy with anti–vascular endothelial growth factor (anti-VEGF) agents has dramatically improved visual outcomes for patients with various retinal vascular diseases, including retinal vascular occlusion, diabetic macular edema, and neovascular age-related macular degeneration. Landmark phase 3 randomized clinical trials comparing anti-VEGF alternatives have answered key questions regarding their comparative effectiveness in these diseases.1-3 However, a remaining issue that faces physicians is how to choose an anti-VEGF dosing regimen that optimizes visual outcomes while avoiding unnecessary procedures and patient visits.